Open-source AI tool competes with leading proprietary models in medical diagnosis

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said Tues­day, tak­ing the rare step of

GSK is gear­ing up to dis­con­tin­ue the brand-name ver­sion of its asth­ma med­ica­tion Flovent, just as the Med­ic­aid re­bate cap is end­ing in Jan­u­ary 2024,